LRRK2 Cohort Consortium
The MJFF-led LRRK2 Cohort Consortium brings research groups together -- sharing resources and troubleshooting common problems -- to speed efforts to move LRRK2 toward therapeutic relevance for patients.
The Consortium comprises three initiatives:
Each cohort includes LRRK2-positive Parkinson's patients, unaffected LRRK2 mutation carriers, idiopathic PD patients and control subjects. The Consortium follows standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson's database and biorepository.
Available Biospecimens and Data
MJFF makes data and biosamples (whole blood, serum, plasma, RNA, CSF and urine) available to the scientific community to conduct research on novel PD biomarkers. Biospecimens and data from the LRRK2 Cross-sectional Study are currently available to qualified members of the research community. Biospecimens and data from the LRRK2 Longitudinal Study will be available to the research community beginning August 2015. 23andMe is currently analyzing its data and samples and will share resources in the near future.
LRRK2 Cohort Consortium Publications
Analysis from the LRRK2 Cohort Consortium has yielded notable findings. Researchers are preparing these papers for publication.
|Paper||Writing Committee Lead||Writing Committee Members||Status|
|Difference between iPD-LRRK2 PD||Connie Marras, MD, PhD||Alcalay, Duda, Fernandez, Ruiz, Saunders-Pullman, Tolosa, Waro||In Preparation|
|Premotor LRRK2 Characterization||Eduardo Tolosa, MD, PhD||Alcalay, Duda, Marras, Mondragon, Saunders-Pullman, Waro||In Preparation|
View a list of all publications and presentations from projects utilizing the resources.
Ongoing Research Utilizing LRRK2 Cohort Consortium Specimens
The following research studies are actively accessing LRRK2 Cohort Consortium samples. Researchers may apply to use biospecimens through the Access to Data and Biospecimens page.
|Project Title||Principal Investigator||Institution||Specimen(s) Used|
|Influence of Immune Subtypes on the LRRK2 Phenotype||Daniela Berg, MD||Centre of Neurology and Hertie-Institute for Clinical Brain Research, University Hospital Tuebingen||Plasma|
|Peripheral blood-based gene transcript biomarkers for prediction of Parkinson disease in LRRK2 mutation carriers||Avi Orr-Urtreger MD, PhD||Tel Aviv Sourasky Medical Center||RNA|
|Alpha-synuclein and other biomarkers in biological samples of LRRK2 PD||Eduardo Tolosa, MD, PhD||Hospital Clinic Universitari de Barcelona||CSF|
|Effect of LRRK2 mutations on PD-associated inflammation||Nicolas Dzamko, PhD||Neuroscience Research Australia||CSF, serum|
|aSyn 3'UTR modulation in LRRK2 carriers as a potential biomarker||Asa Abeliovich, MD, PhD||Columbia University Medical Center||RNA|
|LRRK2 in urine as a biomarker for PD||Andrew West, PhD||University of Alabama, Birmingham||Urine|
|Purine biomarkers of LRRK2 PD||Michael Schwarzschild, MD, PhD||Mass General Institute for Neurodegenerative Disease||Plasma|
|Analysis of A-beta, tau and p-tau in CSF samples from the LRRK2 Cohort Consortia||Dr. Leslie Shaw, PhD||University of Pennsylvania||CSF|
|NeuroX Profiling of Samples from the PPMI Prodromal and Genetic Cohorts, the LRRK2 Cohort Consortium, and the BioFIND Cohort||Andrew Singleton PhD||National Institute on Aging||DNA|
|Whole exome sequencing and analysis of PPMI Prodromal and Genetic Cohorts, PPMI Genetic Registry, and LRRK2 Cohort Consortium samples||Andrew Singleton PhD||National Institute on Aging||DNA|
|LRRK2 biomarker initiative- Detection of LRRK2 in cerebral spinal fluid and urine||Jean-Marc Taymans PhD||INSERM||Urine|